Agilent Beats Q3 Estimates, But Profitability Metrics Draw Scrutiny

Agilent Technologies, Inc. (NYSE: A) reported fiscal third-quarter results that exceeded Wall Street estimates, confirming a sustained recovery in its top-line performance. The life sciences and diagnostics company posted earnings per share (EPS) of $1.62 on revenue of $1.88 billion, beating consensus forecasts of $1.49 and $1.84 billion, respectively.

Revenue Recovery Confirmed

The Q3 results, released after the market close on August 26, marked the third consecutive quarter of accelerating EPS for Agilent. The figures represent an 8.7% beat on earnings and a 2.2% beat on revenue.

This performance reinforces the company's turnaround narrative following a period of contraction. According to an analysis by Investing.com, after Agilent's revenue declined by 4.7% in fiscal 2024, the current annualized revenue run-rate of approximately $7.5 billion is consistent with the full-year consensus estimate of $7.45 billion for fiscal 2026.

Margin and Cash Flow Concerns

Despite the strong revenue growth, the company's profitability metrics have not kept pace, raising questions for investors. Key areas of concern highlighted in the Investing.com analysis include:

Ad

• Gross Margins: Slipped from 54.3% in fiscal 2024 to 52.4% in fiscal 2025.
• Return on Equity (ROE): Declined from 23.6% to 20.6% over the same period.
• Free Cash Flow: Decreased from $1.37 billion to $1.15 billion.

These figures suggest that the top-line recovery has not yet fully translated into improved profitability, a factor the market will be watching closely.

Outlook and Valuation

Investors are now looking ahead to Agilent's fourth-quarter earnings, tentatively scheduled for November 30, which will provide crucial guidance for fiscal 2027. Consensus estimates project Q4 EPS of $1.71 on revenue of $1.97 billion.

While analyst estimates have seen modest upward revisions, the stock's valuation reflects much of the positive news. Trading at a trailing price-to-earnings ratio of 30.9x, an Investing.com fair-value model pegs the stock at $145.64, suggesting it may be overvalued at its recent price of $157.57. Further upside may depend on the company demonstrating a clear path to margin expansion.